Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18458490 | 0.93 | SIGMAR1 (0.52) | SIGMAR1OPRM1FAAHCYP3A4HSD17B10 | |
| SCHEMBL18458505 | 0.90 | MC4R (0.56) | SIGMAR1OPRM1FAAHCYP3A4HSD17B10 | |
| SCHEMBL18458725 | 0.90 | SIGMAR1 (0.47) | SIGMAR1OPRM1CYP3A4 | |
| SCHEMBL18425580 | 0.90 | SIGMAR1 (0.54) | SIGMAR1OPRM1FAAHCYP3A4HSD17B10 | |
| SCHEMBL18458497 | 0.87 | SIGMAR1 (0.52) | SIGMAR1OPRM1FAAHMC4RDRD4 | |
| SCHEMBL18458324 | 0.87 | SIGMAR1 (0.53) | SIGMAR1OPRM1FAAHPOLB | |
| SCHEMBL18458974 | 0.87 | CHRNB2 (0.46) | SIGMAR1OPRM1LMNAMAPTOPRL1 | |
| SCHEMBL18458734 | 0.85 | SMN1; SMN2 (0.51) | SIGMAR1FAAH | |
| SCHEMBL18458731 | 0.85 | SIGMAR1 (0.52) | SIGMAR1OPRM1CYP3A4HSD17B10MC4R | |
| SCHEMBL18458530 | 0.84 | FAAH (0.53) | SIGMAR1OPRM1FAAHDRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017016669-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | SIGMAR1 5/4885OPRM1 1/4885FAAH 80/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | SIGMAR1 5/4885OPRM1 1/4885FAAH 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.